The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee

Published:2020-09 Issue:9 Volume:15 Page:1409-1424
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Sholl Lynette M.,Hirsch Fred R.,Hwang David,Botling Johan,Lopez-Rios Fernando,Bubendorf Lukas,Mino-Kenudson Mari,Roden Anja C.,Beasley Mary Beth,Borczuk Alain,Brambilla Elisabeth,Chen Gang,Chou Teh-Ying,Chung Jin-Haeng,Cooper Wendy A.,Dacic Sanja,Lantuejoul Sylvie,Jain Deepali,Lin Dongmei,Minami Yuko,Moreira Andre,Nicholson Andrew G.,Noguchi Masayuki,Papotti Mauro,Pelosi Giuseppe,Poleri Claudia,Rekhtman Natasha,Tsao Ming-Sound,Thunnissen Erik,Travis William,Yatabe Yasushi,Yoshida Akihiko,Daigneault Jillian B.,Zehir Ahmet,Peters Solange,Wistuba Ignacio I.,Kerr Keith M.,Longshore John W.

Funder

Merck Sharp & Dohme

Roche

AstraZeneca

Boehringer Ingelheim

Illumina

Merck

Novartis

Pfizer

EMD Serono

Takeda

Amgen

Johnson & Johnson

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference97 articles.

1. NCCN guidelines updates: new immunotherapy strategies for improving outcomes in non-small cell lung cancer;Gubens;J Natl Compr Canc Netw,2019

2. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Planchard;Ann Oncol,2019

3. Five-year overall survival for patients with advanced nonsmall-cell lung cancer treated with pembrolizumab: results from the Phase I KEYNOTE-001 study;Garon;J Clin Oncol,2019

4. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab;Topalian;JAMA Oncol,2019

5. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC;Camidge;Nat Rev Clin Oncol,2019

Cited by 209 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nano-enabled regulation of DNA damage in tumor cells to enhance neoantigen-based pancreatic cancer immunotherapy;Biomaterials;2024-12

2. Fatty acid metabolism affects hepatocellular carcinoma progression via the PPAR-γ signaling pathway and fatty acid β-oxidation;International Immunopharmacology;2024-11

3. Plasma proteome-based test (PROphetNSCLC) predicts response to immune checkpoint inhibitors (ICI) independent of tumor programmed death-ligand 1(PD-L1) expression and tumor mutational burden (TMB);2024-09-11

4. Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line therapy for extensive-stage small–cell lung cancer (ES-SCLC): a phase II trial;eClinicalMedicine;2024-09

5. Predictive value and molecular correlates of MYC immunohistochemistry and copy number gain in non-small cell lung carcinomas treated with immunotherapy;Lung Cancer;2024-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3